Allergy or Allergic rhinitis is caused by sensitivity to a number of environmental factors including grass, tree and weed pollens, house
dust mite and cat dander. Prevalence in adults can range from 17 - 40% and is region/climate dependent. For those patients failing
to respond to symptomatic treatments e.g. antihistamines Allergen-specific immunotherapy can be an effective alternative which
involves long term treatment with SLIT or SCIT based products.
Current market leaders in Allergen-specific immunotherapies are ALK-Abello (Denmark) and Stallergenes (France).
Both are currently focused on global expansion strategies for their existing products e.g. Grazax/Oralair but also new product
development to address the major unmet need of a more convenient administration profile(s).
This MarketVIEW product is a comprehensive commercial opportunity assessment detailing the current market for Allergen-specific
immunotherapies with a patient based value/volume forecast for all relevant allergens/administration routes to 2025. The model takes
into account significant future events including penetration into new countries/regions and launch of new products. A discussion is
also included with regard to latest epidemiology; review of regulatory/reimbursement/pricing issues and a focus on key early
stage/late stage R&D development programs.
THIS PRODUCT IS COMPOSED OF SUMMARY PRESENTATION + 1 MODEL (optional)
*Prices are quoted for either presentation or forecast model separately and are for 1 region license only. Regions are North America, or EU or ROW.
For UK orders VAT will be added at 20%.
Please review the TERMS and CONDITIONS of purchase.